ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
As part of an R&D restructuring program announced last year, Sanofi-Aventis will close its research facility in the Great Valley region of Pennsylvania within the next year, eliminating 400 jobs. The 57 employees in the company’s clinical-supply-related business in Great Valley will not be affected, and the company says it is offering 303 employees relocation options. Meanwhile, Lonza reported to the Pennsylvania Department of Labor this month that it will eliminate 106 jobs at its Conshohocken active pharmaceutical ingredients facility, which it announced last January that it would close. The firm has said that its Shawinigan, Quebec, and Wokingham, England, facilities would also be affected by a company-wide program that targets 175 jobs (C&EN, Jan. 18, page 16).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X